Across TCGA pan-cancer cohorts, P2RX7 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated P2RX7 data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher P2RX7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated P2RX7 expression acts as an unfavorable survival marker.
UCEC, ACC, and BLCA are the cancer types where P2RX7 Mutation most reproducibly stratifies survival.